Evenity (Romosozumab) VA Coverage Pathway

What Evenity Is and Why Access Gets Managed Closely

Romosozumab is a monoclonal antibody that blocks sclerostin, a protein that normally suppresses bone formation. Blocking it gives Evenity a dual effect that most osteoporosis drugs don't have: it increases new bone formation while also reducing bone breakdown.

The FDA approved Evenity in April 2019 for postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture, multiple fracture risk factors, or failure of or intolerance to other osteoporosis therapies [2]. Bone loss and fall-related fractures in older adults carry a large health and cost burden nationally, which is part of why a drug with strong trial results in this population draws attention despite its price.

Evenity is expensive relative to older osteoporosis drugs. Reported cash and list prices for the monthly two-syringe dose have run in the range of roughly $1,800 to $2,000, with a full 12-month course costing tens of thousands of dollars at cash-pay rates. Treat any specific number here as a starting point, not a quote. Drug pricing changes, and the actual amount a veteran or insurer pays depends on current WAC/AWP pricing, negotiated federal pricing, and the specific plan involved, none of which is fixed information suitable for a static article.

The FRAME trial (N=7,180) found that romosozumab reduced new vertebral fractures by 73% compared with placebo at 12 months (0.5% vs. 1.8%, P<0.001) [4]. The ARCH trial (N=4,093), which compared romosozumab to alendronate, found a 48% lower risk of new vertebral fractures at 24 months in the group that started on romosozumab and then switched to denosumab [5]. These are large effect sizes for an osteoporosis drug, which is the clinical argument VA providers make when pursuing access for high-risk patients despite the formulary restriction.

The Endocrine Society's 2019 guideline update discusses anabolic agents like romosozumab as a reasonable initial option, ahead of antiresorptive therapy, for postmenopausal women at very high fracture risk [6]. That guideline position is part of what VA reviewers weigh during a non-formulary request, though it does not override a facility's own criteria-for-use protocol.

How VA Drug Formulary Decisions Work

The VA National Formulary is managed by VA Pharmacy Benefits Management (PBM) Services. Drugs on the national formulary are available at VA medical centers without extra authorization. Drugs that are not on it, which is where Evenity sits at most facilities, need additional clinical justification before a pharmacy will fill them.

Each VA medical center and Veterans Integrated Service Network also runs its own Pharmacy and Therapeutics (P&T) Committee. These local committees can add a drug to a local formulary or set up criteria-for-use (CFU) protocols that define which patients qualify. Romosozumab generally falls under a CFU protocol rather than being freely prescribable. In practice, this means your VA provider can order Evenity, but the order triggers a review before it gets dispensed.

The specific documents required, review timeline, and committee structure differ by facility and change over time. Ask your VA pharmacy service directly what the current criteria-for-use protocol requires at your facility rather than assuming the steps below are identical everywhere.

Step-by-Step: Getting Evenity Through the VA

Step 1: Establish clinical eligibility. Your provider documents that you meet criteria for romosozumab, typically a confirmed postmenopausal osteoporosis diagnosis (T-score of -2.5 or below on DXA at the spine, femoral neck, or total hip), evidence of high fracture risk (prior fragility fracture or an elevated FRAX score), and a history of trying or being unable to tolerate first-line agents such as alendronate, risedronate, or zoledronic acid [7].

Step 2: Non-formulary drug request. Your provider submits a request through the VA's electronic health record system to the facility's P&T Committee or a designated clinical pharmacist. The request typically needs your DXA results, fracture history, FRAX score, and documentation of prior osteoporosis treatment.

Step 3: Cardiovascular screening. Because Evenity carries an FDA black box warning for cardiovascular events, VA facilities generally want confirmation that you have not had a myocardial infarction or stroke within the past year. The ARCH trial found major adverse cardiac events in 2.5% of romosozumab patients versus 1.9% of alendronate patients over the first 12 months, a difference that drove the boxed warning [5].

Step 4: P&T Committee review. Review timelines vary by facility, and any specific number of business days quoted to you should be confirmed with your own facility rather than assumed from this article. If the request is denied, your provider can appeal with additional clinical justification.

Step 5: Administration. Evenity is given as two subcutaneous injections (thigh, abdomen, or upper arm) by a health care professional, typically at a VA outpatient or infusion clinic. Completing the course requires 12 monthly visits.

Verification Checklist Before You Rely on This Page

Some facts about Evenity are stable and unlikely to change from one review cycle to the next. Others are tied to insurer policy, pricing, or a specific facility, and can go out of date within months. Use this table to sort what you're looking at before you act on it or repeat it to a veteran.

Stable facts (clinical and federal, unlikely to change year to year):

• FDA approval date (April 2019) and the approved indication (postmenopausal women at high fracture risk)
• Mechanism of action (sclerostin inhibitor with a combined anabolic and antiresorptive effect)
• The black box warning for myocardial infarction, stroke, and cardiovascular death, and the contraindication in patients with an MI or stroke in the past year
• The 12-month maximum treatment duration
• The FRAME and ARCH trial results as published (fracture reduction and cardiovascular event rates)
• The general VA structure of a National Formulary plus local criteria-for-use protocols for restricted drugs
• The federal rule barring manufacturer copay cards from being applied to government insurance, including VA, Medicare, and Medicaid

Date-sensitive facts (verify before quoting to a veteran or patient):

• Current cash or list price per dose
• The specific VA copay dollar amount for your priority group and any annual out-of-pocket cap
• Whether your specific VA facility has added Evenity to a local formulary or changed its criteria-for-use requirements
• Current non-formulary request turnaround time at your facility
• Your specific TRICARE plan's specialty-tier copay amount
• The current Medicare Part B annual deductible
• Whether a romosozumab biosimilar has since reached the market
• Current income thresholds, dollar caps, and eligibility rules for the Amgen Evenity Complete copay card and the Amgen Safety Net Foundation

Where this article states a specific dollar figure or timeline, treat it as illustrative rather than current unless you have checked it against a live source (VA.gov, your facility's pharmacy service, your insurer, or the manufacturer's program page) on the day you need it.

What Veterans Typically Pay

VA prescription cost-sharing depends on your priority group and disability rating, and it tends to be more favorable than commercial insurance for a high-cost biologic like this one.

As a general and long-standing VA policy, veterans with a service-connected disability rating of 50% or higher, and veterans receiving a medication for a service-connected condition, are not charged a copay for that prescription. Former prisoners of war, veterans receiving aid and attendance or housebound benefits, and veterans below the VA means-test income threshold also commonly qualify for $0 copays. For other enrolled veterans, VA outpatient prescriptions are billed on a tiered copay schedule with an annual cap. The exact dollar amounts in that schedule change periodically, so confirm the current tier amounts and cap directly through VA.gov or your facility rather than treating any number here as current.

Because Evenity is administered in a clinical setting rather than picked up at a pharmacy window, it may be billed differently than a typical dispensed prescription. Ask your VA pharmacy or billing office how your facility handles cost-sharing for in-clinic biologic injections.

By comparison, commercial insurance plans that place Evenity on a specialty coinsurance tier (commonly 25% to 33%) can leave a patient responsible for several hundred dollars per monthly injection until an out-of-pocket maximum is reached. This is one of the practical reasons the VA pathway, despite the extra administrative steps, is often worth pursuing for eligible veterans.

Non-VA Insurance Pathways for Veterans With Dual Coverage

Some veterans have both VA enrollment and private insurance through an employer, a spouse's plan, or Medicare. If a private plan covers Evenity, you can choose to use that benefit instead of, or alongside, VA care.

Most commercial plans and Medicare Part B cover Evenity as a physician-administered injectable under the medical benefit rather than the pharmacy benefit. Medicare Part B typically pays 80% of the Medicare-approved amount after the annual Part B deductible is met, leaving a 20% coinsurance responsibility; a Medigap plan may cover some or all of that remainder. The exact current deductible amount changes annually and should be checked at Medicare.gov. TRICARE covers Evenity under its pharmacy benefit with prior authorization, with a specialty copay tier that varies by TRICARE plan (Prime, Select, or TRICARE For Life).

For commercially insured veterans, Amgen's Evenity Complete program offers copay assistance that can meaningfully reduce out-of-pocket cost. This type of manufacturer copay assistance cannot be applied to government insurance, including VA, Medicare, Medicaid, or TRICARE, under federal anti-kickback rules. If you carry both VA and commercial coverage, some veterans use the commercial plan with copay assistance for Evenity specifically while using VA benefits for other medications. Confirm current program terms directly with Amgen before counting on a specific savings amount.

Patient Assistance for Veterans Without VA or Insurance Coverage

Veterans who are not enrolled in VA health care, or who don't have prescription drug coverage there, may be able to use Amgen's Safety Net Foundation, which provides Evenity at no cost to patients who meet income eligibility and lack insurance coverage for the drug. Income thresholds, required documentation, and processing times for this kind of program change over time, so verify current eligibility rules and paperwork requirements directly with the foundation before advising a patient on them.

Sequencing Therapy After the 12-Month Course

Evenity is approved for a maximum of 12 months of continuous use. Bone density gains made during treatment tend to decline if no follow-up antiresorptive therapy is started afterward. Follow-up analyses of the FRAME trial reported that patients who transitioned from romosozumab to denosumab maintained and built on their bone density gains through 24 months, while those who stopped without a follow-up agent lost a meaningful portion of those gains [4]. If you want the exact extension-study citation for this specific follow-up finding, ask your reviewing clinician to confirm it, since it is a distinct publication from the primary FRAME trial referenced here.

Access to follow-up agents through the VA is generally more straightforward than access to Evenity itself. Alendronate and risedronate are VA National Formulary agents. Denosumab and zoledronic acid are typically available through a criteria-for-use protocol rather than as a restricted non-formulary request. The 2020 AACE/ACE guideline update recommends transitioning patients who complete a course of romosozumab to an antiresorptive agent such as denosumab or a bisphosphonate to help preserve the bone density gains [7]. Ask your VA provider what the sequencing plan looks like before you start romosozumab, not after you finish it.

Cardiovascular Risk: What the VA Will Screen For

According to its FDA black box warning, romosozumab carries a potential risk of myocardial infarction, stroke, and cardiovascular death. The warning contraindicates romosozumab use in patients with a history of MI or stroke in the past 12 months [2]. The ARCH trial documented adjudicated major adverse cardiovascular events in 2.5% of romosozumab-treated participants compared with 1.9% receiving alendronate during the initial 12-month period [5]. Clinical recommendations suggest balancing romosozumab's cardiovascular signal against its fracture-prevention benefits, especially when considering patients who lack a history of cardiovascular disease.

VA providers typically order a baseline cardiovascular risk assessment, which may include a review of cardiac history, blood pressure, a lipid panel, and possibly an EKG or cardiology consult, before submitting the non-formulary request. Veterans with an MI or stroke in the past year will not qualify for romosozumab through the VA. Those with controlled risk factors such as treated hypertension or hyperlipidemia may still be eligible, but expect closer documentation.

If you are on Evenity, report new chest pain, sudden severe headache, vision changes, one-sided weakness, or shortness of breath right away rather than waiting for a scheduled visit.

Tips for a Smoother VA Approval Process

Bring complete DXA scan reports, not just the summary page, to your VA appointment. If your DXA was done outside the VA, have it sent to your VA provider or uploaded through the VA Health Connect portal. Document dates of prior fractures with imaging confirmation (X-ray, CT, or MRI), and if you've tried a bisphosphonate before, note the specific drug, dose, duration, and reason it was stopped.

Ask your provider to calculate and include your FRAX score in the request. A 10-year major osteoporotic fracture probability above 20%, or a hip fracture probability above 3%, strengthens the clinical case for an anabolic agent over a standard antiresorptive [7].

If your request is denied, ask your provider to file a formal appeal with any new clinical data and a written rationale referencing current Endocrine Society or AACE guidance on anabolic-first therapy for very high-risk patients. Your facility's VA Patient Advocate can also help navigate an appeal.